The incidence of hematologic malignancies (leukemias, lymphomas and myelomas) in the Kingdom of Saudi Arabia (KSA) is on the rise. For example, according to the Saudi Cancer Registry, leukemia was the 5th most common cancer diagnosed in both genders between the years of 1999-2013. Hodgkin’s lymphoma accounts for 3.6% of all cancers in KSA and is the 7th most common cancer in Saudi males and the 8th most common cancer in Saudi females.
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of leukemias, lymphomas, and myelomas, including current Saudi guidelines for selected malignancies.
This program is supported by Novartis.